10x Genomics, Inc. (TXG)
NasdaqGS
Price as at 13 Aug 2026, 08:16 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
10x Genomics, Inc. trades at USD57.75. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
12 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Cathie Wood, ARK Investment Management LLC$383.52M · 2.5% of book
- Ken Griffin, CITADEL ADVISORS LLC$106.56M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$74.70M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$71.04M · 0.1% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$30.75M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own TXG?
12 of the institutions we track reported a position in TXG in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its TXG data?
Fundamentals for TXG come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 13 Aug 2026, 08:16 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for TXG, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.